Form 4: Supernus Pharmaceuticals SVP, Chief Medical Officer Jonathan Rubin Reports Stock Transactions

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities, including performance share units and restricted stock units.

Summary

• Jonathan Rubin, a Senior Vice President and Chief Medical Officer at Supernus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 21, 2025, Rubin acquired 1,875 shares of common stock upon settlement of performance share units and sold 927 shares to cover tax withholding at a price of $39.15 per share.
• He also acquired 750 shares on February 22, 2025, 1,250 shares on February 22, 2025, and 1,250 shares on February 23, 2025.
• These acquisitions were related to the vesting of restricted stock units.
• Following these transactions, Rubin directly owns 11,103 shares of Supernus common stock.
• He also holds derivative securities including 0 Performance Share Units, 750 Restricted Stock Units, 3,750 Restricted Stock Units, and 2,500 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to stock-based compensation. The sale of shares to cover taxes is a common practice and doesn't necessarily indicate a negative outlook.

Positives

• The acquisition of shares through vesting of performance share units and restricted stock units indicates confidence in the company's performance.

Negatives

• The sale of 927 shares to cover tax obligations could be perceived negatively, although it's a common practice.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis, with services like Bloomberg, FactSet, and Thomson Reuters providing data and analytics on insider trading activity.
• Comparing Rubin's transactions to those of other executives at Supernus and peer companies can provide insights into management's overall sentiment and expectations for the company's future performance.
• For example, if multiple executives are consistently purchasing shares, it could signal strong confidence in the company's prospects, while widespread selling could raise concerns.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock.

Key Dates

Keywords

Form 4, beneficial ownership, Supernus Pharmaceuticals, SUPN, Jonathan Rubin, stock transactions, performance share units, restricted stock units, SVP, Chief Medical Officer